文献速递病毒性肝炎艾滋病与性传播感染

慢性丙型肝炎感染男性及丙肝病毒清除后的睾酮变化

Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该队列纳入327例慢性HCV感染男性(其中HIV合并感染150例),并对85例有治疗前及获得持续病毒学应答(SVR)后睾酮检测的男性进行分析,中位随访36个月。结果显示活动性HCV者总睾酮(TT)和性激素结合球蛋白(SHBG)较高而游离睾酮(FT)无差异;SVR后TT与SHBG显著下降而FT不变,低FT在SVR后仍常见且持续存在。

要点

  • 活动性HCV感染时SHBG升高可能掩盖睾酮缺乏,应结合FT评估。
  • SVR后TT与SHBG显著下降,但FT未见改善。
  • 低FT在SVR后仍常见且持续,成功治疗后仍需筛查。

核心结论

  • 活动性HCV感染期间SHBG升高可能掩盖睾酮缺乏。
  • 尽管SVR后SHBG改善,低FT仍常见并在HCV清除后持续存在。
  • 提示慢性HCV成功治疗后需提高认识并使用FT估计值进行筛查。

研究设计与样本

  • 研究为队列研究,纳入327例慢性HCV感染男性,其中HIV合并感染150例。
  • 对85例有治疗前及SVR后睾酮检测的男性子集进行纵向分析。
  • 中位随访36个月,临床试验注册号NCT01350648。

主要发现

  • 基线活动性HCV者较已获SVR者TT更高(P < .0001)、SHBG更高(P < .0001),而FT无差异。
  • 低TT(<10.4 nmol/L)在SVR者中较活动性HCV者更常见(P = .002)。
  • 低FT(<0.1735 nmol/L)常见:活动性HCV 50%、SVR 43%,组间无差异。
  • 纵向分析中TT和SHBG显著下降(P < .0001),FT在SVR后保持不变。
  • 低FT在SVR后持续存在(治疗前58%、SVR后54%,P = .72)。

关键数值与推荐

  • 低TT定义为<10.4 nmol/L,低FT定义为<0.1735 nmol/L。
  • 低FT患病率:活动性HCV 50%,SVR 43%。
  • SVR前后低FT:治疗前58%,SVR后54%(P = .72)。

临床怎么用

  • 慢性HCV男性治疗前后评估睾酮时应使用FT估计值而非仅依赖TT。
  • HCV成功治疗后仍应筛查低FT,尤其合并HIV或肝纤维化指标变化者。

局限性

  • 原文摘要未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) and hepatic dysfunction are associated with low total and free testosterone (TT and FT) and high sex hormone-binding globulin (SHBG). However, little is known about changes in testosterone following successful HCV treatment. METHODS: We evaluated testosterone levels and the prevalence of low testosterone in a cohort of 327 men with chronic HCV infection (human immunodeficiency virus [HIV] coinfection = 150) and in a subset of 85 men with testosterone levels obtained pre-HCV treatment and after sustained virologic response (SVR). Median follow-up was 36 months. RESULTS: Participants with active HCV at baseline had higher TT (P < .0001) and SHBG (P < .0001) compared with participants who had achieved SVR, whereas FT did not differ. Low TT (<10.4 nmol/L) was more prevalent in participants with SVR compared with active HCV (P = .002); however, low FT (<0.1735 nmol/L) was common (50% active HCV, 43% SVR) and did not different between groups. For participants with longitudinal determinations, TT and SHBG decreased significantly (P < .0001) while FT remained unchanged post-SVR. Low FT persisted after SVR (pre-treatment 58%, post-SVR 54%, P = .72). HIV status and change in aspartate aminotrasferase-to-platelet ratio were significant independent predictors of change in FT following SVR. CONCLUSIONS: During active HCV infection, testosterone deficiency may be masked due to elevated SHBG. Despite improvements in SHBG following SVR, low FT was common and persisted after HCV clearance, indicating the need for enhanced awareness and screening using estimates of FT following successful treatment of chronic HCV. CLINICAL TRIALS REGISTRATION: NCT01350648.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chaudhury CS, Mee T, Chairez C, et al. Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance. Clin Infect Dis. 2019. PMID: 30715229. doi:10.1093/cid/ciy965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。